Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Abstract 1067: PDK-1 targeting with SNS-510 in sarcoma

Elgilda Musi, Pietro Taverna, Gary K. Schwartz

Cancer Res (2021) 81 (13_Supplement): 1067.

https://doi.org/10.1158/1538-7445.AM2021-1067

Published: 01 July 2021

View articletitled, Abstract 1067: PDK-1 targeting with SNS-510 in sarcoma

Journal Articles

Abstract 317: Vecabrutinib inhibits C481 mutated Bruton's tyrosine kinase and its downstream signaling in vitro

Burcu Aslan, Mikhila Mahendra, Michael D Peoples, Joe R. Marszalek, Christopher P Vellano, Xiaofeng Zheng, Jing Wang, Pietro Taverna, Varsha Gandhi

Cancer Res (2019) 79 (13_Supplement): 317.

https://doi.org/10.1158/1538-7445.AM2019-317

Published: 01 July 2019

View articletitled, Abstract 317: Vecabrutinib inhibits C481 mutated Bruton's tyrosine kinase and its downstream signaling in vitro

Journal Articles

Abstract 4677: Integrated molecular profiles and guadecitabine response in relapsed/refractory acute myeloid leukemia

Woonbok Chung, Andrew D. Kelly, Patricia Kropf, Pietro Taverna, Sue Naim, Mohammad Azab, Jaroslav Jelinek, Hagop M. Kantarjian, Jean-Pierre J. Issa

Cancer Res (2017) 77 (13_Supplement): 4677.

https://doi.org/10.1158/1538-7445.AM2017-4677

Published: 01 July 2017

View articletitled, Abstract 4677: Integrated molecular profiles and guadecitabine response in relapsed/refractory acute myeloid leukemia

Journal Articles

Abstract 2776: Genetic correlations with clinical response to ASTX727 in patients with myelodysplastic syndromes (MDS)

Haley E. Ramsey, Shilin Zhao, Yaomin Xu, Olatoyosi Otoyosi, Philip Amrein, Amy Dezern, Laura Michaelis, David P. Steensma, Stefan Faderl, Guillermo Garcia-Manero, James Lowder, Pietro Taverna, Michael R. Savona

Cancer Res (2017) 77 (13_Supplement): 2776.

https://doi.org/10.1158/1538-7445.AM2017-2776

Published: 01 July 2017

View articletitled, Abstract 2776: Genetic correlations with clinical response to ASTX727 in patients with myelodysplastic syndromes (MDS)

Journal Articles

Abstract 4347: Epigenetic targeting of DNMT1 in adipocytes inhibits high-grade serous ovarian cancer cell migration and invasion through TIMP3 upregulation

Jessica Tang, Fang Fang, Aaron Buechlein, Pietro Taverna, Kenneth P. Nephew

Cancer Res (2017) 77 (13_Supplement): 4347.

https://doi.org/10.1158/1538-7445.AM2017-4347

Published: 01 July 2017

View articletitled, Abstract 4347: Epigenetic targeting of DNMT1 in adipocytes inhibits high-grade serous ovarian cancer cell migration and invasion through TIMP3 upregulation

Journal Articles

Abstract 4675: Novel combination therapy of DNA methyltransferase inhibitor guadecitabine (SGI-110) and PARP inhibitor talazoparib (BMN-673) for BRCA-proficient high-grade serous ovarian cancer

Nicholas Pulliam, Pietro Taverna, John Lyons, Kenneth P. Nephew

Cancer Res (2017) 77 (13_Supplement): 4675.

https://doi.org/10.1158/1538-7445.AM2017-4675

Published: 01 July 2017

View articletitled, Abstract 4675: Novel combination therapy of DNA methyltransferase inhibitor guadecitabine (SGI-110) and PARP inhibitor talazoparib (BMN-673) for BRCA-proficient high-grade serous ovarian cancer

Journal Articles

Abstract 2325: Immune checkpoint(s) expression in AML patients enrolled in a phase 1-2 study with guadecitabine

Carolina Fazio, Alessia Covre, Maria Lofiego, Pietro Taverna, Mohammad Azab, James N. Lowder, Sandra Coral, Michele Maio

Cancer Res (2016) 76 (14_Supplement): 2325.

https://doi.org/10.1158/1538-7445.AM2016-2325

Published: 15 July 2016

View articletitled, Abstract 2325: Immune checkpoint(s) expression in AML patients enrolled in a phase 1-2 study with guadecitabine

Journal Articles

Abstract 2952: Determinants of hypomethylation and clinical responses in relapsed/refractory AML patients treated with SGI-110, a novel hypomethylating agent in a phase 1/2 study

Woonbok Chung, Pietro Taverna, John Lyons, Yong Hao, Mohammad Azab, Hagop Kantarjian, Patricia Kropf, Jean-Pierre Issa

Cancer Res (2015) 75 (15_Supplement): 2952.

https://doi.org/10.1158/1538-7445.AM2015-2952

Published: 01 August 2015

View articletitled, Abstract 2952: Determinants of hypomethylation and clinical responses in relapsed/refractory AML patients treated with SGI-110, a novel hypomethylating agent in a phase 1/2 study

Journal Articles

Abstract 2943: Novel combination therapy of DNMT inhibitor SGI-110 and PARP inhibitor BMN-673 (talazoparib) for BRCA-proficient ovarian cancer

Nicholas Pulliam, Pietro Taverna, John Lyons, Kenneth P. Nephew

Cancer Res (2015) 75 (15_Supplement): 2943.

https://doi.org/10.1158/1538-7445.AM2015-2943

Published: 01 August 2015

View articletitled, Abstract 2943: Novel combination therapy of DNMT inhibitor SGI-110 and PARP inhibitor BMN-673 (talazoparib) for BRCA-proficient ovarian cancer

Journal Articles

Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy

Gail Roboz, Hagop Kantarjian, Patricia Kropf, Ellen Richie, Nitin Jain, Elizabeth Griffiths, Nikola A. Podoltsev, Katherine Walsh, Casey O'Connell, Wendy Stock, David Rizzieri, Raoul Tibes, Todd Rosenblat, Woonbok Chung, Pietro Taverna, Xiang Yao Su, Sue Naim, Mohammad Azab, Jean-Pierre Issa

Cancer Res (2015) 75 (15_Supplement): CT321.

https://doi.org/10.1158/1538-7445.AM2015-CT321

Published: 01 August 2015

View articletitled, Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy

Journal Articles

Abstract 2533: SGI-110 priming sensitizes hepatocellular carcinoma cells to oxaliplatin

Yuting Kuang, Anthony El-Khoueiry, Pietro Taverna, Mats Ljungman, Nouri Neamati

Cancer Res (2015) 75 (15_Supplement): 2533.

https://doi.org/10.1158/1538-7445.AM2015-2533

Published: 01 August 2015

View articletitled, Abstract 2533: SGI-110 priming sensitizes hepatocellular carcinoma cells to oxaliplatin

Journal Articles

Abstract 2317: SGI-110 alters ovarian cancer stem cells to prevent recurrent and chemoresistant ovarian cancer

Yinu Wang, Horacio Cardenas, Fang Fang, Salvatore Condello, Pietro Taverna, Gavin Choy, Mohammad Azab, Kenneth Nephew, Daniela Matei

Cancer Res (2014) 74 (19_Supplement): 2317.

https://doi.org/10.1158/1538-7445.AM2014-2317

Published: 01 October 2014

View articletitled, Abstract 2317: SGI-110 alters ovarian cancer stem cells to prevent recurrent and chemoresistant ovarian cancer

Journal Articles

Abstract 3756: The DNA hypomethylating agent SGI-110, reverses the platinum resistance of ovarian cancer models

Joanne M. Munck, John Lyons, Neil T. Thompson, Nicola G. Wallis, Pietro Taverna

Cancer Res (2014) 74 (19_Supplement): 3756.

https://doi.org/10.1158/1538-7445.AM2014-3756

Published: 01 October 2014

View articletitled, Abstract 3756: The DNA hypomethylating agent SGI-110, reverses the platinum resistance of ovarian cancer models

Journal Articles

Abstract 2320: Clinical epigenetic resensitization of platinum-resistant, recurrent ovarian cancer patients with SGI-110, a novel, second-generation, subcutaneously administered hypomethylating agent (HMA)

Gini Fleming, Sharad Ghamande, Yvonne Lin, Angeles Alvarez Secord, John Nemunaitis, Merry-Jennifer Markham, Kenneth Nephew, Fang Fang, Shweta Gupta, Sue Naim, Gavin Choy, Simone Jueliger, Pietro Taverna, Yong Hao, Harold Keer, Mohammad Azab, Daniela Matei

Cancer Res (2014) 74 (19_Supplement): 2320.

https://doi.org/10.1158/1538-7445.AM2014-2320

Published: 01 October 2014

View articletitled, Abstract 2320: Clinical epigenetic resensitization of platinum-resistant, recurrent ovarian cancer patients with SGI-110, a novel, second-generation, subcutaneously administered hypomethylating agent (HMA)

Journal Articles

Epigenetic Targeting of Ovarian Cancer Stem Cells

Yinu Wang, Horacio Cardenas, Fang Fang, Salvatore Condello, Pietro Taverna, Matthew Segar, Yunlong Liu, Kenneth P. Nephew, Daniela Matei

Cancer Res (2014) 74 (17): 4922–4936.

https://doi.org/10.1158/0008-5472.CAN-14-1022

Published: 01 September 2014

View articletitled, Epigenetic Targeting of Ovarian Cancer Stem Cells

Includes: Supplementary data

Journal Articles

Abstract 680: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent, in hematologic malignancies.

Alessia Covre, Giulia Parisi, Hugues Jmg Nicolay, Ester Fonsatti, Elisabetta Fratta, Luca Sigalotti, Pietro Taverna, Sandra Coral, Michele Maio

Cancer Res (2013) 73 (8_Supplement): 680.

https://doi.org/10.1158/1538-7445.AM2013-680

Published: 15 April 2013

View articletitled, Abstract 680: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent, in hematologic malignancies.

Journal Articles

Abstract 678: Evaluation of oral bioavailability and intermittent dosing schedules for pharmacodynamic effects by SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA), in male cynomolgus monkeys .

Aram Oganesian, Pietro Taverna, Mohammad Azab

Cancer Res (2013) 73 (8_Supplement): 678.

https://doi.org/10.1158/1538-7445.AM2013-678

Published: 15 April 2013

View articletitled, Abstract 678: Evaluation of oral bioavailability and intermittent dosing schedules for pharmacodynamic effects by SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA), in male cynomolgus monkeys .

Journal Articles

Abstract 2095: A phase 2 study of Amuvatinib (MP-470), the first RAD51 inhibitor in combination with platinum-etoposide (PE) in refractory or relapsed small cell lung cancer (ESCAPE).

Lauren Byers, Leora Horn, Jitendra Gandhi, Goetz Kloecker, Taofeek K. Owonikoko, Saiama Waqar, Maciej J. Krzakowski, Gavin Choy, Nancy Cecchettini, Pietro Taverna, Amarpal Sahai, Mojtaba Noursalehi, Mohammad Azab, D. Ross Camidge

Cancer Res (2013) 73 (8_Supplement): 2095.

https://doi.org/10.1158/1538-7445.AM2013-2095

Published: 15 April 2013

View articletitled, Abstract 2095: A phase 2 study of Amuvatinib (MP-470), the first RAD51 inhibitor in combination with platinum-etoposide (PE) in refractory or relapsed small cell lung cancer (ESCAPE).

Journal Articles

Abstract 679: SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome .

Carmen S. Tellez, Marcie J. Grimes, Maria A. Picchi, Yushi Liu, Tom H. March, Aram Oganesian, Pietro Taverna, Steven A. Belinsky

Cancer Res (2013) 73 (8_Supplement): 679.

https://doi.org/10.1158/1538-7445.AM2013-679

Published: 15 April 2013

View articletitled, Abstract 679: SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome .

Journal Articles

Abstract 4623: The novel, small molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.

Jessica Tang, Fang Fang, Yinu Wang, Pietro Taverna, David F.B. Miller, Gavin Choy, Mohammad Azab, Daniela Matei, Katherine S. Pawelczak, Pamela VanderVere-Carozza, Michael Wagner, John J. Turchi, Kenneth P. Nephew

Cancer Res (2013) 73 (8_Supplement): 4623.

https://doi.org/10.1158/1538-7445.AM2013-4623

Published: 15 April 2013

View articletitled, Abstract 4623: The novel, small molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 1067: PDK-1 targeting with SNS-510 in sarcoma

Abstract 317: Vecabrutinib inhibits C481 mutated Bruton's tyrosine kinase and its downstream signaling in vitro

Abstract 4677: Integrated molecular profiles and guadecitabine response in relapsed/refractory acute myeloid leukemia

Abstract 2776: Genetic correlations with clinical response to ASTX727 in patients with myelodysplastic syndromes (MDS)

Abstract 4347: Epigenetic targeting of DNMT1 in adipocytes inhibits high-grade serous ovarian cancer cell migration and invasion through TIMP3 upregulation

Abstract 4675: Novel combination therapy of DNA methyltransferase inhibitor guadecitabine (SGI-110) and PARP inhibitor talazoparib (BMN-673) for BRCA-proficient high-grade serous ovarian cancer

Abstract 2325: Immune checkpoint(s) expression in AML patients enrolled in a phase 1-2 study with guadecitabine

Abstract 2952: Determinants of hypomethylation and clinical responses in relapsed/refractory AML patients treated with SGI-110, a novel hypomethylating agent in a phase 1/2 study

Abstract 2943: Novel combination therapy of DNMT inhibitor SGI-110 and PARP inhibitor BMN-673 (talazoparib) for BRCA-proficient ovarian cancer

Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy

Abstract 2533: SGI-110 priming sensitizes hepatocellular carcinoma cells to oxaliplatin

Abstract 2317: SGI-110 alters ovarian cancer stem cells to prevent recurrent and chemoresistant ovarian cancer

Abstract 3756: The DNA hypomethylating agent SGI-110, reverses the platinum resistance of ovarian cancer models

Abstract 2320: Clinical epigenetic resensitization of platinum-resistant, recurrent ovarian cancer patients with SGI-110, a novel, second-generation, subcutaneously administered hypomethylating agent (HMA)

Epigenetic Targeting of Ovarian Cancer Stem Cells

Abstract 680: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent, in hematologic malignancies.

Abstract 678: Evaluation of oral bioavailability and intermittent dosing schedules for pharmacodynamic effects by SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA), in male cynomolgus monkeys .

Abstract 2095: A phase 2 study of Amuvatinib (MP-470), the first RAD51 inhibitor in combination with platinum-etoposide (PE) in refractory or relapsed small cell lung cancer (ESCAPE).

Abstract 679: SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome .

Abstract 4623: The novel, small molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only